Antibody-mediated killing using NK cells, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.
Antibody-mediated killing using NK cells, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.
Our newest line of investigational products are an innovative combination of our CD8+ T cell and NK cell platforms in a single genetic engineered platform that incorporates all the features of our NK cell platform together with a CAR with the resulting
Immunotherapeutic vaccine
Vaccines are usually prophylactic.
The purpose of vaccination is to prevent future infections
by providing active acquired immunity (immunologic memory) to a particular disease.
In contrast, immunotherapeutic vaccines are administered to patients who already have diseases.
Immunotherapeutic vaccines treat various infectious
diseases and cancers through enhancing patients’ immune responses.
DrHarvard™ Platform Technology
DrHarvard immunotherapeutic vaccine is a personalized medicine that uses patient’s own cells (autologous immune cells). It helps patient’s immune system to find out and eliminate cancer cells.
DrHarvard is composed of three parts: Antigen presenting cells (APCs), tumor-associated antigen genes, and adjuvant.
It uses autologous lymphocytes (patient’s B cells & monocytes) as APCs. APCs process foreign antigens and/or impaired cells into peptide fragments and present them to immune cells.
APCs of DrHarvard have tumor-specific antigen genes. They present tumor antigens to immune cells and activate them to eliminate specific tumor cells.
α-galactosylceramide is an adjuvant which potentiate the anti-tumor activities of DrHarvard.
Tumor cells overexpress specific tumor antigens on their surface and by changing the inserted tumor antigen genes, DrHarvard can be used for various cancers.
DrHarvard is a platform technology that can be applied to every cancer with identified tumor antigen.
Dr HARVARD is a R&D specialized bioventure company started in a laboratory in the college of pharmacy, Harvard University.
We are developing innovative immunotherapeutic vaccines, Cellon, that can overcome the medical and technical limitations of current cancer and/or infectious diseases therapies.
Cellon is a personalized vaccine which uses patient’s own cells.
It is a powerful and efficient immunotherapeutic vaccine that activates all types of immune cells usable in our immune system with minimum adverse effects.
Our goal is to improve the quality of life of patients suffering from intractable diseases.
To develop personalized immunotherapeutic vaccines for patients with cancers or infectious diseases
that are hard to treat due to medical & technical limitations.
· To introduce new paradigm for immunotherapeutic
vaccines and improve quality of life of patients treated.
To improve technology through consistent research and development
· To become a global leading biotech-company.
Subscribe to stay up to date on the Dr Harvard
Email*
We won’t send you spam. Unsubscribe at any time.
Natural Killer Cells (NK cells), Natural Killer T cells (NKT cells), helper T cells, Antibodies (Abs) are trademarks or registered trademarks of DrHARVAR
Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.
Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.